Progressive fibrosing interstitial lung disease

The PBS subsidises nintedanib for patients with progressive fibrosing interstitial lung disease (PF-ILD).

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with nintedanib under the National Health Act 1953, section 85 for patients with PF-ILD.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing nintedanib.

Treatment specifics

To be eligible for PBS-subsidised treatment with nintedanib, patients must be diagnosed through a multidisciplinary team and be treated either:

  • by a respiratory physician or specialist physician
  • in consultation with a respiratory physician or specialist physician.

A multidisciplinary team is defined as including at least a specialist respiratory physician, a radiologist and where histological material is considered, a pathologist.

If attendance isn’t possible because of geographical isolation, consultation with a multidisciplinary team is required for diagnosis.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised nintedanib to treat progressive fibrosing interstitial lung disease can be made either in:

All written applications must include the completed:

Applying for initial grandfather treatment

Applications for initial grandfather authority approval to prescribe PBS-subsidised nintedanib to treat PF-ILD can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised nintedanib to treat PF-ILD can be made either:

More Information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 November 2022